Artificial Intelligence-Enabled Electrocardiography for Detection of Left Ventricular Diastolic Dysfunction: A Systematic Review and Meta-Analysis
Edjimbi Johann, Nisarg Shah, Luca Donisi, Aryan Gajjar, Claudia See, Alyssa A Grimshaw, Hassim Bachir Diop, Antonio Luiz P Ribeiro, Eloi Marijon, Gari Clifford, Bamba GayeAbstract
Background
Left ventricular diastolic dysfunction (LVDD) is an early precursor to heart failure with preserved ejection fraction (HFpEF) and it is currently diagnosed using echocardiography, a resource-intensive and operator-dependent modality that limits large scale screening. The 12-lead electrocardiogram (ECG) is widely available but lacks sufficient diagnostic accuracy for LVDD. Artificial intelligence (AI)-enhanced ECG analysis has emerged as a potential scalable alternative, although its overall diagnostic performance remains uncertain.
Objectives
To evaluate the diagnostic accuracy of AI-based algorithms for detecting LVDD in a systematic review and meta-analysis.
Methods
We systematically searched eight major databases through August 2025, complemented by forward and backward citation chasing. Studies reporting sensitivity and specificity of AI-ECG models, using echocardiography as the reference standard, were included. Pooled sensitivity, specificity, and area under the summary receiver operating characteristic curve (AUC) were estimated using a bivariate random-effects model.
Results
Five studies including 105,554 participants were analyzed. AI-ECG demonstrated a pooled sensitivity of 0.82 (95% CI: 0.81–0.83) and specificity of 0.77 (95% CI: 0.70–0.82), with an AUC of 0.85 (95% CI: 0.81–0.87). Substantial heterogeneity was observed (I2 = 98.5% for sensitivity and 99.8% for specificity), although results were robust in sensitivity analyses. Predictive values were prevalence-dependent. Negative predictive value was 98.8% at 5% prevalence and 93.7% at 22.2%, but declined to 81.1% at 50% prevalence and 64.7% at 70%.
Conclusion
AI-enhanced electrocardiography demonstrated good diagnostic performance for detecting LVDD and may support future rule-out or risk-enrichment strategies in selected populations. However, current evidence remains insufficient to support routine clinical implementation.